États-Unis · Bourse & Finance · Yahoo Finance

InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China

Publié par Yahoo Finance · États-Unis il y a 10 h

BEIJING, Oct. 11, 2026 (GLOBE NEWSWIRE) -- (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced…

Lire l'article complet sur Yahoo Finance Connectez-vous pour sauvegarder

MediaNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (finance.yahoo.com)

InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China

À lire aussi

XRP Ledger defends emergency patch for unlimited XRP bug

Trump's Russia-Ukraine Energy Ceasefire May Only Cover Oil Refineries

Amazon in talks to acquire AI startup Decart for $7B: WSJ

The movie about a Facebook whistleblower who leaked incriminating details disappoints, and ‘The Social Reckoning’ will likely lag ‘The Social Network’

'SNL' takes aim at Kevin O’Leary and his Utah data center: 'I'm going to make the future go away’

Everyone wants SCOTUS to take up prediction markets: State of Crypto

InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China

Partager

À lire aussi

XRP Ledger defends emergency patch for unlimited XRP bug

Trump's Russia-Ukraine Energy Ceasefire May Only Cover Oil Refineries

Amazon in talks to acquire AI startup Decart for $7B: WSJ

The movie about a Facebook whistleblower who leaked incriminating details disappoints, and ‘The Social Reckoning’ will likely lag ‘The Social Network’

'SNL' takes aim at Kevin O’Leary and his Utah data center: 'I'm going to make the future go away’

Everyone wants SCOTUS to take up prediction markets: State of Crypto